BioSpace News Archive

Turnstone Biologics Corp. and Moffitt Cancer Center announced the formation of a broad strategic alliance, deepening their existing multi-year research collaboration.

Evotec SE, Boehringer Ingelheim, a leading research-driven biopharmaceutical company, and bioMérieux, a world leader in in vitro diagnostics, announced that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance.

Gnubiotics Sciences announced that the Swiss Innovation Agency will support a research collaboration with the University Hospital Zürich to accelerate the development of Gnubiotics’ GLAAD technology in a range of solid tumors.

EW Healthcare Partners, has announced that Athene Merger, Inc., an affiliate of EW, has extended the expiration date of its tender offer to purchase all issued and outstanding shares of TherapeuticsMD, Inc., at a price of $10.00 per share until one minute after 11:59 PM, New York City time, on July 12, 2022, unless further extended in accordance with the terms of the Merger Agreement and the applicable rules and regulations of the SEC.

Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced the appointment of Maria Törnsén, an industry executive with 20 years of global commercial experience in U.S. and ex-U.S. markets, to its Board of Directors, effective July 5, 2022.

Zomedica Corp., a veterinary health company offering diagnostic and therapeutic products for companion animals, announced that the acquisition of the assets of Revo Squared LLC was recently completed.

Immuneering Corporation, a biopharmaceutical company using translational bioinformatics to advance a pipeline of product candidates designed to benefit large populations of patients with cancer and other diseases, announced that management will participate in William Blair Biotech Focus Conference 2022.

Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today that its leading BET inhibitor, ZEN-3694, is being evaluated in seven NCI sponsored clinical trials for safety and efficacy in multiple oncology indications with significant unmet need, through the NCI’s Cancer Therapy Evaluation Program (CTEP).

Bio-Techne today announced the European launch of the CE-IVD marked RNAscope ISH Probe High Risk HPV, intended for use in patients diagnosed with oropharyngeal squamous cell carcinoma (OPSCC) to aid in the identification of high-risk human papillomavirus (HPV).

Mindset Pharma Inc. announced today that the United States Patent and Trademark Office (“USPTO”) has granted allowance for Mindset’s patent application number 17/387,864, titled “3-Pyrrolidine-Indole Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders.”